Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Endometrial Serous Adenocarcinoma	NCIT_C27838	[A high grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.]
Recurrent Endometrial Adenocarcinoma	NCIT_C158437	[The reemergence of endometrial adenocarcinoma after a period of remission.]
RET Mutation/Fusion Inhibitor BLU-667	NCIT_C132295	[An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, BLU-667 binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers.]
RET Inhibitor	NCIT_C159438	[Any agent that inhibits the receptor tyrosine kinase rearranged during transfection (RET).]
Atypical Pituitary Gland Adenoma	NCIT_C132296	[A usually aggressive and invasive pituitary gland adenoma characterized by excessive p53 immunoreactivity, increased mitotic activity, and MIB-1 proliferative index greater than 3%.]
Pituitary Gland Adenoma	NCIT_C3329	[A non-metastasizing tumor that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland. The tumor can be hormonally functioning or not. The diagnosis can be based on imaging studies and/or radioimmunoassays. Due to its location in the sella turcica, expansion of the tumor mass can impinge on the optic chiasm or involve the temporal lobe, third ventricle and posterior fossa A frequently associated physical finding is bitemporal hemianopsia which may progress to further visual loss.]
Plasma Cell Enrichment	NCIT_C132297	[Concentration of plasma cells in a sample for the purpose of the detection of cytogenetic abnormalities.]
CDISC Protocol Terminology	NCIT_C132298	[The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) protocol group.]
Clinical Data Interchange Standards Consortium Terminology	NCIT_C61410	[The terminology that includes terms relevant to the Clinical Data Interchange Standards Consortium.]
Protocol Identifier	NCIT_C132299	[A sequence of letters, numbers, or other characters that uniquely identifies a study protocol.]
Carbonic Anhydrase I Deficiency	NCIT_C132290	[Decreased or absent activity of the enzyme carbonic anhydrase 1, due to loss-of-function mutation(s) in the gene CA1.]
Procaine Merethoxylline	NCIT_C132291
Presynaptic Congenital Myasthenic Syndrome 6	NCIT_C132292	[Congenital myasthenic syndrome caused by mutation(s) in the CHAT gene, encoding choline O-acetyltransferase. It is inherited in an autosomal recessive manner.]
Congenital Myasthenic Syndrome	NCIT_C84647	[A group of rare genetic neuromuscular disorders characterized by neuromuscular junction defects. The defects are classified as presynaptic, synaptic, or postsynaptic. Signs and symptoms include muscle weakness, easy fatigability, feeding and respiratory difficulties, and scoliosis.]
CHAT Gene	NCIT_C104885	[This gene is involved in neurotransmitter biosynthesis.]
Napsagatran Anhydrous	NCIT_C132279
Oxeclosporin	NCIT_C132271
Iometopane I 123	NCIT_C132272
Milameline	NCIT_C132273
Cholinergic Agonist	NCIT_C47796	[Any agent that is capable of activating cholinergic receptors (nicotinic and muscarinic) or of enhancing or prolonging the actions of acetylcholine.]